Enobosarm - Veru Healthcare
Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024Latest Information Update: 10 Feb 2025
At a glance
- Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.; Veru Healthcare
- Class Antineoplastics; Nitriles; Obesity therapies; Small molecules; Urologics
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
- Phase II Obesity
- Discontinued Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Urinary-Stress-Incontinence